What Is Tirzepatide? 1 Shot That Acts Like Two Hormones
The shot changes insulin, hunger, and stomach emptying. Large studies measured blood sugar and weight.
What Tirzepatide changes in your body
What is Tirzepatide? It's a weekly prescription shot. The medicine does the jobs of two gut hormones. GLP-1 is the first. It helps release insulin after meals and slows stomach emptying. Older GLP-1 shots often copy that hormone alone. Both hormones may ease hunger.
The FDA first cleared Tirzepatide in May 2022 for type 2 diabetes. The weight clearance arrived in November 2023. Sleep apnea came later.
Large studies found lower long-term blood sugar and body weight. People didn't all get the same result. The sections below tell who joined and how long each study ran.
Those facts can guide your next clinic talk. They can't show whether this drug fits you.
What the Tirzepatide shot is made from
A lab makes Tirzepatide as a peptide, or short protein. Its 39-amino-acid chain has thirty-nine linked protein parts. The design began with a gut hormone. Scientists at Eli Lilly added a fatty part. A blood protein called albumin carries the drug. The fatty part holds them together. The liver and kidneys then remove it slowly. About half leaves in five days [1][16].
Before 2020, Eli Lilly used a research name for Tirzepatide. You may see that old name in early papers [1][2].
Tirzepatide isn't a small pill. The stomach would break its protein apart. That is why the medicine comes as a shot.
The key fact is its slow exit from blood. That makes weekly shots possible. Your body may still feel different.
What lab notes say about Tirzepatide hormones
Tirzepatide activates two gut hormone receptors simultaneously — the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both are G-protein-coupled receptors expressed in the pancreatic beta cells that secrete insulin, in the gut, and in the brain. Activating either receptor in the presence of elevated blood glucose triggers insulin release; activating both together amplifies the insulin secretory response and produces additional metabolic effects.
At the GLP-1 receptor: tirzepatide acts as a biased agonist, preferentially activating the cAMP (cyclic adenosine monophosphate — a second messenger that transmits the hormonal signal inside the cell) pathway over the beta-arrestin pathway (which regulates receptor internalization and desensitization). This bias appears to enhance and prolong insulin secretion by keeping the receptor active at the cell surface longer [2]. GLP-1 receptor activation also suppresses glucagon (the hormone that raises blood glucose), slows gastric emptying, and reduces food intake through central appetite circuits.
At the GIP receptor: tirzepatide engages the GIPR more completely than the GLP-1R — the compound was classified as an imbalanced dual agonist in receptor-occupancy and signalling assays [2]. GIP receptor activation enhances glucose-dependent insulin secretion and may have beneficial effects on fat tissue metabolism. The combination of both receptor pathways in a single molecule is what makes tirzepatide a 'twincretin' or 'dual incretin agonist' rather than just a GLP-1 receptor agonist.
The discovery paper (Coskun 2018) established the proof of concept: in mice, the dual-receptor engagement produced greater weight reduction than a selective GLP-1 receptor agonist, and the 142-subject phase 1 programme in humans showed reduced fasting glucose and body weight versus placebo [1]. The clinical trials then scaled that finding across tens of thousands of participants.
Mechanism explains what the molecule does, not whether it is suitable for a particular person. After an individual evaluation, Promise Peptides clinicians may prescribe Tirzepatide through licensed telehealth; mypromise.com provides information about that service, while the prescribing decision remains clinician-led.
What health problems Tirzepatide can treat
The FDA label names 3 uses for Tirzepatide. Each has phase 3 studies, meaning large tests late in drug study.
- Type 2 diabetes. The May 2022 clearance covers adults. Five large type 2 diabetes studies compared Tirzepatide with other care. That care included a GLP-1 shot, which copies one gut hormone. It also included insulin glargine. This insulin shot works for a long time. The label pairs Tirzepatide with food and activity changes for better blood sugar [7][16].
- Long-term weight care. The November 2023 clearance covers adults with obesity. Some overweight adults also qualify when they have another weight-linked illness. BMI is a rough weight-for-height score. A score of 30 kilograms per square meter met the study rule. A score of 27 kilograms per square meter also met it with a weight-linked illness. Average weight fell 15–21% over 72 weeks. In SURMOUNT-1, the placebo group got no medicine and lost less [4][34].
- Obstructive sleep apnea. The airway closes again and again during sleep. The clearance covers adults with moderate or severe apnea plus obesity. A sleep study found fewer breathing stops [35].
The label doesn't cover type 1 diabetes. Tirzepatide isn't a stand-alone fatty liver treatment. One liver study did find a hopeful result [37]. The type 2 diabetes label also doesn't cover preventing heart attacks or strokes. In high-risk adults with type 2 diabetes, heart studies found no rise in strokes, heart attacks, or deaths from heart disease versus other care. A doctor decides any use not named on the label. The source list names each study.
FDA clearance tells what the agency reviewed. It doesn't say which use fits your case.